Trial Profile
A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Ciclosporin (Primary) ; Verapamil (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 19 Feb 2023 Planned End Date changed from 26 Dec 2022 to 26 Dec 2023.
- 19 Feb 2023 Planned primary completion date changed from 26 Dec 2022 to 26 Dec 2023.